Antibody-drug conjugates (ADCs) consist of monoclonal antibody and cytotoxic drugs covalently attached via stable crosslinkers, and are prospective antibody drugs for cancer therapy. To cover the overall pharmacokinetic understanding of ADCs, both the antibody and the released drugs are necessary for practical clinical observation. The nano-surface and molecular-orientation limited (nSMOL) proteolysis is a universal approach for antibody bioanalysis that enable Fab-selective proteolysis, which maintains antibody sequence specificity while decreasing excess analyte peptides. In this study, we describe quantitative assays for ADC in human plasma using nSMOL for the antibody and polarity-selective liquid-liquid partition with a methanol/ethyl acetate mixed solvent for the cytotoxic drugs. This approach led to the successful development of LC-MS validated bioanalysis of the antibody and released drugs within 20% for lower limit of quantitation and 15% for another concentration setting of Trastuzumab emtansine (T-DM1), Trastuzumab antibody and emtansine conjugated with crosslinker (DM1-MCC). The validated concentration ranges in human plasma were 0.06-250 g/mL for T-DM1 and 0.39-200 ng/mL for DM1-MCC. These results indicate that LC-MS method with a two-sided approach, using nSMOL and liquid-liquid partition, show potential for the precise pharmacokinetic study for ADC development and treatment.
Introduction
Antibody-drug conjugates (ADCs) are the second approach for antibody-based cancer therapy [1] [2] [3] [4] [5] . Tumor antigen-selective antibodies are valuable as specific career proteins to target cytotoxic drugs in cancer cells. They may demonstrate high-efficacy, even though several compounds have dropped out owing to strong cytotoxicity or adverse effects [6] [7] [8] . Additionally, efficient drug candidate screening using chemical libraries in pharmaceutical companies will expand the antibody treatments with conjugated drugs, and this approaches have the potential to lead to a big breakthrough in the future, especially in the field of anticancer agents. However, in order to achieve the desired efficacy of so-called hybrid drugs, detailed pharmacokinetic studies are indispensable. The metabolism of antibodies and cytotoxic anticancer drugs may proceed through fundamentally different pathway. Antibody is degraded in the endoplasmic reticulum via Fc receptor internalization in target or endothelial cells [9] , but many compounds are regulated and metabolized by Cytochrome P450 pathway [10] . And crosslinkers between antibodies and drugs need to be considered the possibility of degradation in the blood because the chemical structure contains amide bonding moiety [11] [12] [13] [14] . Thus the overall pharmacokinetic picture for the antibody and released drugs in circulation should be explored in order to develop the clinical indicators of ADCs. The quantitative analysis of antibody drugs in a biological matrix is basically dependent on the ligand binding assay (LBA). However, this methodology has issues to be improved in principle such as cost effectiveness of method development, inhibition from competitive molecules and matrix, and indirect detection of antibody molecules [15, 16] . However, technological progress such as automation and microtechnology devices has expanded the quantitative range [17] [18] [19] . Even so, overall pharmacokinetic assay by LBA has still insufficient for ADCs.
Liquid chromatography-mass spectrometry (LC-MS) has shown potential for the method development of bioanalysis using only the mass number information of compounds or peptides. Additionally, LC-MS may overcome the basic issues of antibody drug bioanalysis in LBA by direct detection of target molecules [20, 21] . Recently, we have developed a novel LC-MS bioanalysis method independent of a variety of antibody drugs [22] [23] [24] . The chemistry of nano-surface and molecular-orientation limited (nSMOL) proteolysis is designed a Fab-selective proteolysis with maintaining antibody sequence specificity while minimizing additional analyte peptides and trypsin. And, generated peptides can be accurately quantitated by LC-MS from a complexed biological matrix. The full validation assay development and multiplexed quantitation using nSMOL approach have already been completed for more than ten antibody drugs. These results are of significant value for regulatory LC-MS analysis.
nSMOL enables the quantitation of ADCs. However, it can theoretically quantify the antibody, not determine the drug adducts. Furthermore, it is very difficult for analytical sciences to archive the simultaneous single assay of antibody proteins and released compounds with physicochemically and metabolically different properties. Thus, for the acquisition of ADC (antibody and cytotoxic drug) pharmacokinetic information, a broad and regulated LC-MS bioanalysis method should be developed for the antibody and released drugs from ADCs.
In this report, we have discussed the validated analysis of Trastuzumab and released antibody-conjugated drug, emtansine (DM1) from Trastuzumab emtansine (T-DM1), in human plasma by using LC-MS in order to evaluate the pharmacokinetic study.
Materials and methods

Reagents and standard compounds
Trypsin-immoblized glycidyl methacrylate (GMA)-coated nanoferrite particle FG beads with surface activation by NHS (Nhydroxysuccinimide) group was purchased from Tamagawa Seiki (Nagano, Japan) [25] . Toyopearl AF-rProtein A HC-650F resin was from Tosoh (Tokyo, Japan). Trastuzumab-DM1 (T-DM1) was from Chugai Pharmaceuticals (Tokyo, Japan). Individual male and female human plasma (EDTA-2 K treated) was from Kohjin Bio (Saitama, Japan). n-octyl-␤-d-thioglucopyranoside (OTG) was from Dojindo Laboratories (Kumamoto, Japan). P 14 R, an internal standard synthetic peptide, and trypsin from porcine pancreas was from Sigma Aldrich (St. Louis, MO), and chemically modified by reductive alkylation. Ultrafree-MC GV centrifugal 0.22 m filter was from Merck Millipore (Billerica, MA). Ansamitocin P-3 (P-3, MW = 635.15) was from Carbosynth (Compton, UK). Emtansine (DM1) with linker MCC (4-maleimidomethyl)-cyclohexylcarbonyloxy, DM1-MCC, MW = 975.55) was synthesized by one step thiol-maleimide coupling, and purified below. These compounds were store as a 10 mg/mL of dimethyl sulfoxide solution at −30 • C, and prepared at appropriate concentration before use. Chemical structure of these compounds are shown in Fig. 1 . Other reagents, buffers, and solvents were purchased from Sigma-Aldrich and Wako Pure Chemical Industries (Osaka, Japan).
Synthesis of emtansine compound
The synthetic procedures of DM1-MCC are follows (in supplementary material, Fig. 1S 
Signature peptide assignment of antibody drugs
Signature peptide assignment of antibody drugs was carried out according to our previous studies. Briefly, we aligned the amino acid sequences by ClustalW analysis using humanized antibody sequences for T-DM1 (in supplementary material, Fig. 2S ). Tryptic peptide identification was achieved by high-resolution LCMS-IT-TOF MS (SHIMADZU, Kyoto, Japan) and Mascot (Matrix Sciences, London, UK) in-house database server. Using the identified peptide structure, predicted complementarity-determining region (CDR)-containing peptides were selected as candidate signature peptides after comparison with ClustalW results. The selected candidate signature peptides were verified by the addition of each antibody in plasma and the preparation of a set of diluted samples. nSMOL reaction proceeded as follows (in supplementary material, Fig. 3S ): All control and clinical samples were first filtered by 5 m spin devices and then by 0.8 m devices to remove debris. A 10 L aliquot of antibody-spiked human plasma was diluted 10-fold in PBS containing 0.1% OTG. The Ig fraction in plasma was collected in 25 L of PBS-substituted AF-rProtein A resin (50% slurry) with gentle vortexing at 25 • C for 5 min. Nonspecific binding to Protein A resin was washed twice with 300 L of PBS containing 0.1% OTG and then with 300 L of PBS. And washed resin was suspended in 75 L of 25 mM Tris-HCl (pH 8.0) containing 10 fmol/L P 14 R. nSMOL proteolysis was accomplished by 10 g modified trypsin on FG-beads with gentle vortexing at 50 • C for 5 h under saturated vapor atmosphere. nSMOL reaction was quenched by addition of 10% formic acid at a final concentration of 0.5%. The peptide solution was collected by centrifugation (10,000g for 1 min) to remove Protein A resin and trypsin FG-beads. These analytes were transferred into low protein binding polypropylene vials, and then analyzed by LC-MS. Peptide MRM (multiple reaction monitoring) signals with good correlation to drug concentration were selected as the signature peptide transitions of each antibody drugs. Finally, for the setting of MRM transition, we selected the most marked b-or y-ion series fragment as a quantitation, and additional two fragments as structure confirmation.
nSMOL validation setting for whole antibody T-DM1
In our previous validation study for Trastuzumab bioanalysis, peptide IYPTNGYTR (aa.51-59, CDR2 of heavy chain, MRM transition m/z 542.8 > 404.7) was selected and validated as the signature peptide. For the internal standard, P 14 R synthetic peptide (MRM transition m/z 512.1 > 292.3) was used. We used the same conditions to perform the validation assay for T-DM1. 
Structure and monitor ion assignment for released drugs and each internal standard
To analysis the released drugs from T-DM1, we developed LC-MS method for a emtansine with MCC linker (DM1-MCC) and ansamitocin P-3 (P-3) with a maytansine ring only as the internal standard. The fragment assignment of these compounds for the selection of 
Liquid-liquid partition of drugs by organic-aqueous separation
General protein precipitation with a polar solvent like methanol or acetonitrile may leads to extra contamination of water-soluble metabolite. In order to develop a broad and regulated protocol for released drug from ADCs, we focused on the hydrophobic nature of each drugs. Hence, for a methanol/ethyl acetate mixed solvent, the optimal ratio of two solvents was configured in a liquid-liquid partition procedure (in supplementary material, Fig. 4S) . A 320 L of methanol/ethyl acetate mixed solvent was added in 80 L of twofold diluted plasma sample with PBS, and immediately extracted by vigorous vortexing for 5 min. After extraction and partition, sample solution was centrifuged (15,000g x 10 min) for aqueous-organic separation. The organic layer supernatant 300 L was collected and completely dried up by centrifugal evaporator. Dried sample pellet was resuspended by the addition of 100 L of 50% methanol with gentle vortexing for 10 min. The final sample solution was filtered by 0.2 m polytetrafluoroethylene (PTFE) spin devices, and transfer into low-binding glass vials. For T-DM1 assay, 2 ng/mL of P-3 was added as the internal standard. 
Assay for breast cancer patient's plasma samples
Informed consent was obtained from all patients. Patients treated with T-DM1 therapy underwent blood sampling for measurement of trough plasma concentrations after T-DM1 had reached steady-state levels (day 21) for Trastuzumab assay, and just after treatment for DM1-MCC assay. This blood sampling and this study were approved by the Ethic Committee of National Cancer Center Hospital (No. 2014-337). Blood samples were collected in EDTA-containing tubes, and plasma was obtained after centrifuging at 3000 g for 10 min at 4 • C. All plasma samples were stored at −80 • C until analysis.
Results
Validation assay of whole antibody T-DM1
The full validation of T-DM1 by nSMOL proteolysis coupled with LC-MS/MS method was performed in accordance with the Guideline on Bioanalytical Method Validation in Pharmaceutical Development from Notification 0711-1 of the Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, the Ministry of Health, Labour and Welfare, dated July 11, 2013. Briefly, the validation plasma sample sets were prepared and stored at −20 • C or −80 • C for 24 h or longer before each validation assay. The MRM transitions of signature peptides and P 14 R internal standard are shown in Table 1 . In this validation, we verified the calibration linearity, and precision and accuracy test. The data was summarized in Tables 2 and 3 . The quantitation range showed good linearity from 0.061-250 g/mL enough to cover the pharmacokinetic study for T-DM1 [26] . 
Validation assay of DM1-MCC in human plasma
Before the validation assay, we analyzed two compounds by MS/MS analysis, and fragment ion (m/z 547.2) derived from maytansine (19-member ansa macrolide ring) was clearly detected from two compounds (shown in Fig. 2 ). And the extraction yield by liquid-liquid partition using methanol/ethyl acetate mixed solvent was confirmed. The extraction yield with each solvent ratio is shown in Fig. 3(and in supplementary material, Fig. 5S ). As the methanol ratio was increased, the relative ion intensity of emtansine compounds was decreased. Therefore, we determined the extraction condition of 100% ethyl acetate. The time-dependent extraction yield is shown in Fig. 4 . Extraction of DM1-MCC and P-3 were completed within 1 min, so we selected the extraction time between 1 min and 5 min. The addition and repeat recovery rate of DM1-MCC and P-3 were 68.4% and 89.4%, and 92.4% and 99.1%, respectively. The full validation of DM1-MCC by liquid-liquid partition was performed in accordance with same LC-MS guideline in antibody analysis. The MRM transitions of DM1-MCC and P-3 internal standard are shown in Table 4 . DM1-MCC was fully validated in the good linear concentration range from 0.391-200 ng/mL in human plasma enough, which was suitable for the pharmacokinetic study for T-DM1 [27] . All data were summarized in supplementary material, Fig. 6S and 7S, and supplementary tables.
Feasibility study of a clinical application of T-DM1 and free DM1-MCC in breast cancer patients
In order to verify this LC-MS assay reproducibility, we confirmed that assay conditions in experimental validation did not show the inhibition from clinical sample. Clinical verification was performed by the 21 patient's blood samples. Blood samples of breast cancer patients who treated with T-DM1 in National Cancer Center Hospital were collected previously. All plasma concentration of Trastuzumab antibody and DM1-MCC were shown in Fig. 5 . The plasma levels of Trastuzumab and DM1-MCC were obtained comparably with drug information from the package insert of KADCYLA (https://www.accessdata.fda.gov/drugsatfda docs/label/ 2013/125427lbl.pdf). In the repeat assay verifications, Trastuzumab data by nSMOL had Pearson coefficient of r = 0.988 within ±8.89% random repeatability from all patient samples. For released drug assay by liquid-liquid partition, DM1-MCC data had Pearson of r = 0.785 within ±14.0% random repeatability. DM1-MCC data was unavailable for two patient samples. These verifications indicate that LC-MS coupled with nSMOL and liquid-liquid partition assay for ADCs may be sufficiently applicable for regulated clinical research.
Discussion
The conjugation of antibodies with cytotoxic drug has emerged as an important strategy for novel cancer therapies that target specific protein careers. Many clinical trials of ADCs have been successful, with the production of effective literature for several compounds.
In this report, we discuss the broad protocols for overall picture of antibody-drug conjugate T-DM1 pharmacokinetics of antibody and released compounds. Whole antibodies can be analyzed by Fab-selective proteolysis nSMOL coupled with LC-MS approach, which is independent of a variety of antibodies. We applied the validated LC-MS condition of Trastuzumab to T-DM1 bioanalysis. For high MW protein bioanalysis, the definition of internal standard is essential strategy. Ideally, it is desirable to use Trastuzumab with stable isotope (SI) labels. And it is still more desirable that SI labels are minimally labeled in the signature peptides regions because protein conformational and proteolysis yield might be changed by isotopes. And more, it is further preferable that SI labels are on carbon or nitrogen atoms, and remained on the fragment ions after MS/MS analysis to avoid the interference of MRM transitions. However, using SI-labeled signature peptides and/or substrate containing signature peptides, the peak intensity between signature peptides from antibody proteolysis and spiked peptides are quite different because the ion intensity of signature peptides by proteolysis should be controlled by many parameters such as denature, solubility, solvent composition, proteolysis efficiency, or physical adsorption, etc. Based on these consideration, we normally use the unnatural synthetic peptide P 14 R only for the correction of ion intensity in antibody LC-MS bioanalysis.
The released cytotoxic drugs from ADCs are satisfactory quantified by a simple polarity-selective liquid-liquid partition with methanol/ethyl acetate mixed solvent. This approach enables the simple and effective LC-MS bioanalysis in a biological matrix without any special solid-phase extraction cartridge selection or devices. Thus, it has a potential applicability to many ADCs and compounds because of the liquid-liquid separation using the polarity of each compound, which required only the adjustment of two-solvent ratio. According to pharmacokinetic information of T-DM1 in package insert with HER2-positive recurrent breast cancer patients, plasma concentration of DM1-MCC-Lys (DM1-MCC with lysine) was almost N.D. We hypothesized that cleavage reaction from DM1-MCC to DM1 free thiol is relatively slow because of the steric hindrance by a maleimide group, but that metabolic or secondary reaction is more rapid because of a reactive thiol group. And considering from the chemical structure of emtansine, this compound has several potential catabolic sites of amide bonding to Trastuzumab via lysine -amino group, thioether structure between MCC linker and DM1, ester moiety near the maytansine ring, dehalogenation, hydroxylation on allyl group, or demethylation on methoxy group. Most potential catabolism may be occurred by the mitochondrial enzyme in target cancer cells after internalization with T-DM1 [28] . And this reaction may be required the two or more step involving amide bond hydrolysis and reactions on metabolic pathways. Based on the these chemical, metabolic, and clinical considerations, we have decided that DM1-MCC analysis with rapid and accurate ability is most likely to obtain the real PK information for clinical and practical indicators.
This two-sided approach offers a good linearity with sufficient quantitative range for each of each ADC pharmacokinetic studies. The method was verified in samples from patients with breast cancer. These results demonstrated effective pharmacokinetic study The asterisks (*) show that structure confirmation transitions were selected from a parent ion with sodiation, and fragment ions with sodiation and protonation.
using the quantitative and validated LC-MS assay for antibody and released drug comparably with T-DM1 pharmacokinetic data.
Conclusion
We have developed a feasible and convenient LC-MS method for the quantitative analysis of antibody and releasing conjugated drug from ADC in patients with breast cancer. This method could provide a fairly robust procedure for determining Trastuzumab and released DM1-MCC in breast cancer patients. The assay is suitable to analyze the plasma concentration of T-DM1 to evaluate the correlation between the pharmacokinetics and efficacy and/or adverse events of T-DM1.
